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Introduction
Skeletal muscle, adipose tissue and liver are the quantitatively major targets for insulin action in vivo and regulation of critical steps in intermediary metabolism within these tissues account for many of the impacts of insulin on metabolic homeostasis. Many other tissues including the heart express insulin receptors and their functions may be importantly regulated by insulin. In this review we summarize the evidence that the heart is an important target of insulin action and that abrogation of these actions is important in disease states.
Current understanding of the molecular basis of insulin actions on its target cells is drawn from a large literature emanating from studies of the major target tissues and also from a wide range of other cell types including studies of w x appropriately transfected and immortalized cell lines 1-4 . We introduce the basic concepts of the molecular basis of insulin actions, not to reiterate the extensive reviews recently published but rather to highlight aspects which are distinctive or which are poorly-defined in the heart. Our understanding of the biochemical mechanisms by which insulin exerts its effects in the heart are still substantially dependent upon extrapolation from studies of other cell types. It is important to recognize where such extrapolations may require qualification; we therefore focus particularly on the specific features of the myocardium which may lead to a distinct perspective of insulin action in this tissue.
The context of insulin actions in the heart
The actions of any individual external signal must be viewed in the context of a complex set of signals to which cells are exposed in vivo. Three issues are introduced Ž . undoubtedly many more might deserve comment to illustrate the importance of considering the basis against which we must attempt to judge the actions of insulin in the Ž . Ž . heart: i the constant pumping function of the heart, ii the role of intracellular calcium ions in regulating heart Ž . function, and iii the complex interplay of major systems for cell-cell communication in which the heart plays a central role.
Insulin actions and the mechanical demands of the heart
The fact that the function of the heart must proceed uninterrupted dictates a perpetual 'high basal' level of contractile activity and therefore of energy metabolism. In a human heart, basal cardiac output is generally in the range 5-6 litresrmin and may rise by 4-5 times this level in exercise. The function demanded of the heart is reflected by remarkably dense vascularization of the myocardium and a very high reliance on oxidative metabolism indicated by abundance of mitochondria, which occupy w x close to 30% of myocardial cell volume 5 . The perpetual contractile function of the myocardium poses an intriguing set of challenges to understanding of the regulation of metabolism and other cellular functions. Unlike studies of the function of skeletal muscle at the onset of vigorous contraction, comparable studies of the myocardium must examine the effects of modulators within an especially dynamic context-implying that we must be cautious in the interpretation of results of studies with isolated myocardial cells which perform little or no external work.
Calcium ions and insulin action in the heart
In the human heart, calcium release and sequestration must occur at a rate of 40-80 cyclesrmin under resting conditions and as rapidly as 180-220 cyclesrmin in nonpathological exercise stresses. The potential actions of insulin on heart metabolism or function must therefore be exerted against a 'calcium background' which is distinct from that of other insulin target tissues. Many actions of insulin in liver and adipose tissue are achieved with minimal shifts in concentrations of free cytoplasmic Ca 2q and indeed may be antagonised by hormones which patently w x act through increases in cytoplasmic calcium levels 6-8 . One significant challenge is therefore to understand the features of insulin action in the heart which allow interfacing with potentially antagonistic or interacting signals-for example, is calcium sufficiently localized to prevent inappropriate actions or are the regulatory mechanisms substantially different in the heart?
Insulin and additional inter-cellular control systems
The actions of insulin in the heart must be exerted within a complex network of local, neural and endocrine signalling systems. Local and neural signals in the heart include those initiated at the sinoatrial node and also by release of sympathetic adrenergic as well as muscarinic w x neurotransmitters 9 . In turn, myocardial cells may respond with the production of adenosine and other intrinsic w x feedback modulators 10,11 . The heart is also a key endocrine element in the regulation of blood pressure and volume in which it interacts with the kidneys and vascular smooth muscle by communications which feature the actions of the cardiac atrial natriuretic peptides, the reninw x angiotensin system and aldosterone among others 12,13 . There is also emerging evidence that insulin may influence tissue blood flow, perhaps by affecting production of nitric w x oxide in the vascular endothelium 14,15 . Finally, like other tissues, the heart is sensitive to the nutritional status of the individual and the associated regulatory mechanisms for whole-body fuel homeostasis and for local control of energy metabolism.
Indirect actions of insulin on the heart

Ž .
Two issues are emphasized in this section: i the effects of insulin on the supply of substrates for cardiac Ž . energy metabolism and ii the impact of insulin on myocardial perfusion.
The role of insulin in the supply of metabolic substrates to the heart
Insulin plays a major role in regulating the balance of metabolic fuels received by the myocardium; principally through its actions on adipose tissue, skeletal muscle and Ž . liver Fig. 1 . The effects of insulin on protein metabolism, in skeletal muscle and liver may be especially significant in regulating substrate availability to the heart. The ability Ž of insulin to suppress protein degradation and to promote . protein synthesis profoundly affects overall carbohydrate w x and nitrogen economy 16,17 . In insulin deficiency, therefore, the increase in supply of amino acids from net protein catabolism provides precursors for hepatic gluconeogenesis and ketogenesis and contributes to the balance of substrates delivered to the myocardium.
Also critical is the extent to which insulin inhibits Ž adipose tissue triglyceride hydrolysis regulating the ac-. tions of lipolytic hormones because this action dictates levels of long-chain fatty acids released to enter a complex with circulating serum albumin. The loss of regulation of adipose tissue lipolysis is most exaggerated in poorly-controlled insulin-dependent diabetes or cachexia, but is also evident in post-absorptive metabolism in the normal 24-w x hour cycle 16,18 . The increased availability of fatty acids leads to enhanced b-oxidation at the expense of pyruvate oxidation in cardiac myocytes and other cells with sufficient oxidative capacity. The 'glucose-fatty acid cycle' w x 19,20 therefore provides a critical mechanism to conserve Ž . Overall movements from major tissues top via circulating pool to the Ž . Ž . heart. Net reactions stimulated q or inhibited y by increases in plasma insulin in vivo.
Ž glucose for cells with less metabolic flexibility neurones . and blood cells, for example .
Increases in circulating free fatty acids in insulin deficiency have important effects on the liver which also contribute to changes in substrate delivery to the heart. Particularly important is the stimulation of synthesis and export of complex lipoproteins by elevated delivery of free w x fatty acids to the liver 21,22 . During starvation, the circulating lipoprotein-triglycerides are predominantly accessed by skeletal and cardiac muscles because lipoprotein lipase activity is maintained in these tissues but declines in w x adipose tissue 23,24 . In diabetes, however, functional lipoprotein lipase declines in skeletal muscle and heart as well as in adipose tissue-thus contributing significantly w x to diabetic hyperlipoproteinemia 25 . In extended starvation and most markedly in uncontrolled insulin-dependent diabetes or infection, exaggerated oxidation of fatty acids w x leads to increases in circulating ketones 16,26,27 . Ke-Ž tones are extensively released by the liver as a result of the need to conserve levels of free coenzyme A by conden-. sation of acetyl units and contribute to the exclusion of carbohydrate oxidation by the myocardium. Remarkably, mortality from ketoacidosis in developed countries is still Ž in the range of 2-5% and as high as 6-24% in developing . countries , more than half of the cases of ketoacidosis being accounted for by infection and newly-diagnosed w x diabetes 28 .
The role of insulin in the regulation of myocardial perfusion
In view of the reliance of the myocardium on oxidative metabolism, a significant restriction to myocardial blood flow has serious consequences for the function and indeed the survival of cardiac myocytes. Acute and chronic effects of insulin may be significant in contributing to the adequacy of perfusion of the coronary circulation. There is increasing evidence that, in the short-term, insulin may w x stimulate blood flow through skeletal muscle 14 by enhancing the formation of nitric oxide in vascular endothew x lium 29 and therefore inducing relaxation of the associated vascular smooth muscle. It will be important to establish if similar effects are induced directly in myocardial vascular smooth muscle, but the response systems are certainly present and there appear to be complex functions w x for nitric oxide within the myocardium 15 . More generally, insulin may contribute to tonic control of vascular Ž smooth muscle and peripheral blood pressure and there-. fore the load against which the heart must pump . Certainly, insulin resistance is frequently associated with hyw x pertension 30,31 and agents directed at correcting insulin w x resistance may correct defects in blood pressure 32,33 .
In addition to direct effects on vascular tone, defects in insulin secretion or action may contribute significantly to Ž . the pathogenesis of macrovascular atherosclerosis and x microvascular disease 30,31 . The decline in vascular function progresses over many years, ranging from modest changes in responsiveness and permeability to loss of elasticity and outright occlusion. The consequences of this process include compromised perfusion and function of the heart and finally necrosis of tissue significantly deprived of blood flow. A detailed discussion is beyond the scope of this review, but suffice to say that there is compelling evidence to suggest that loss of insulin sensitivity may play a key role in the development of abnormalities which are major risk factors for atherosclerosis-notably hyperinsulinemia, hypertriglyceridemia, elevated VLDL, re-Ž . duced HDL and associated cholesterol levels , impaired glucose tolerance or frank hyperglycemia and hypertension w x 30,31,34,35
Direct actions of insulin on the heart
This section will focus on the role of insulin in the regulation of myocardial energy metabolism and especially on the rapid effects of insulin on the specific activities of Ž . key enzymes and transporters Fig. 2 The energy metabolism of the heart is dominated by oxidation of fatty acids, which accounts for more than 80% of ATP production under most physiological conditions; because of its aerobic capacity the heart is also able to and may amount to 25-50 g glucose consumed in a 24-hour period in humans.
Our understanding of the mechanisms for the pre-eminence of fatty acids as energy fuel for the myocardium was initiated with the seminal observation that glucose oxidation by the perfused heart was markedly impaired by addition of fatty acids or ketones to the perfusion medium w x 39-41 . These and subsequent studies led to the concept w x of the 'glucose-fatty acid cycle' 19,20 , which has been validated in numerous studies including those in vivo w x 42-44 .
We now examine selected steps in cardiac metabolism which are insulin-sensitive, notably glucose transport and key enzymes involved in glycogen metabolism, glycolysis, Ž pyruvate oxidation and b-oxidation of fatty acids Fig. 2 . and Table 1 .
Glucose transport
Early studies established that insulin stimulated the w x uptake of glucose by perfused rat hearts 45, 46 . In many of the earlier studies, 'non-working' hearts were perfused by the Langendorff method, with glucose as the sole substrate. The sharp rise in intracellular concentrations of Ž glucose following insulin stimulation from basal levels of . -1 mM to as high as 12 mM suggested that glucose metabolism was limited by glucose transport in the ab-Ž sence of insulin, and that hexokinase or further 'down-. stream' metabolic enzymes contributed importantly to flux control following insulin stimulation. This concept has been confirmed in studies of individual myocardial cells w x 46 although results of further studies indicate that the w x distribution of control strength is more complex 47 .
The currently accepted mechanism of regulation of glucose transport by insulin was proposed on the basis of w x studies with white adipose cells 48,49 . The stimulation of glucose transport by insulin is accounted for largely by the Ž . movement or translocation of glucose transporter GLUT molecules from intracellular membranes to the plasma membrane and in adipocytes the effect of insulin is largely explained by movement of the specific GLUT-4 isoform w x 50-52 . Studies of specifically labelled GLUTs have been used to discriminate exocytosis from endocytosis and suggest that insulin markedly stimulates the former branch of the cycle while modestly inhibiting the latter and that GLUT molecules likely pass through a complex system of w x intracellular compartments 53,54 .
Translocation of GLUTs has been demonstrated in perw x w x fused hearts 55 , in isolated cardiac myocytes 56 and in w x the heart in vivo 57,58 . The distinct architecture of muscle cells may require special consideration in interpreting the basic model developed from studies of adipocytes. In muscle cells, the intracellular reserve of GLUTs appears in tubulo-vesicular structures associated with the transw x Golgi network 56,59 . Further, the T-tubule system of muscle cells may contribute importantly as a destination w x for insulin-stimulated relocation of GLUTs 60,61 . Studies of other systems for intracellular trafficking of proteins imply a major role for Rab-family GTPases and other w x proteins in membrane docking, fusion and budding 62,63 . In fact, proteins related to the VAMPs of synaptic vesicles w x w x 64 and also Rab-family GTPases 57 have been demonstrated in adipocyte membrane fractions which contain GLUT-4, while the p21-Ras GTPase has been implicated in stimulation of GLUT-4 by insulin in cardiac myocytes w x 65 .
Compared to other insulin-responsive tissues, heart muscle expresses among the highest levels so far detected, w x of the 'insulin-sensitive' GLUT-4 isoform 66,67 . The Ž ratio of GLUT-1rGLUT-4 in heart muscle approximately . 1:3 , means that the expression of the GLUT-1 isoform is also substantial in the heart. Activation of myocardial glucose transport by insulin involves translocation of both w x GLUT-1 and GLUT-4 isoforms 57,58 . High levels of GLUT-1 in the heart probably contribute to the high rates of glucose transport in the absence of insulin, and the Ž . relatively small response to insulin 3-4-fold compared to Ž . skeletal muscle or adipose tissue 10-40-fold . An important caveat, in view of the ability of fatty acids to suppress w x glucose utilization by heart and skeletal muscle 38-40 , is that basal rates of myocardial glucose utilization may be artificially inflated by the absence of lipid substrates in vitro.
An important characteristic of muscle cells is exerciseinduced stimulation of GLUT-4 translocation which is insulin-independent. Exercise-induced activation of glu-( )cose transport has been best demonstrated in skeletal musw x cle 68,69 . Similarly, increases in cardiac work are associw x ated with increased glucose consumption 36,37 and contraction-induced regulation of GLUT-4 has also been shown in cardiac myocytes and appears to preclude further activaw x tion by insulin 70 . The significance of insulin stimulation of myocardial glucose transport must therefore be considered in the context of the effects dictated by mechanical demands of the heart-especially as catecholamines and calcium ions may also activate GLUT-4 translocation indew x pendently of insulin 71 .
The role of insulin in expression of GLUT proteins has also been studied by examining direct effects of the hormone in vitro and changes seen in starvation and diabetes, when rates of glucose transport into the heart are markedly w x Ž reduced 45,72 . The expression of GLUT-1 but not that . of GLUT-4 declined in the heart with 48 hours starvation w x 67 . In these studies, basal glucose transport was diminished, but maximal stimulation by insulin was not markedly affected. The marginal effects of starvation on cardiac GLUT-4 expression are therefore similar to the effects on skeletal muscle and distinct from changes in adipose tissue, in which GLUT-4 levels decline appreciably in starvaw x tion 73 . Induction of diabetes with STZ is also reflected by divergent regulation of GLUT expression in heart and fat. STZ diabetes results in markedly decreased expression w x of GLUT-4 protein and mRNA in adipose tissue 74,75 while more variable results have been reported in skeletal w x muscle 75-78 and essentially no changes detected in the heart, at least over a period of several days after STZ w x treatment 78,79 . Distinct regulation of glucose transport within heart compared with skeletal muscle has been re-Ž . ported in studies of human Type-I insulin-dependent w 18 x diabetics analysed by distribution of F deoxyglucose, using positron emission tomography. In these studies, glucose uptake into skeletal muscle was insulin-resistant during euglycemic, hyperinsulinemic clamps but that into w x heart muscle appeared normal 80 .
Glycogen metabolism
It has long been recognized that the concentration of glycogen in the heart is increased in insulin-dependent diabetes, while the corresponding reserves in liver and w x skeletal muscle become markedly depleted 81 . Rates of glycogen accumulation in the heart can be increased even without increases in glucose uptake, provided an alternative fuel is available to allow re-direction of glucose from w x glycolysis to glycogen synthase 82 . This may be an important mechanism to allow glycogen conservation and repletion in the heart during and following exercise, when lactate release from skeletal muscles is likely to be inw x creased 83 .
Despite the maintenance of steady-state levels of glycogen in the diabetic heart, the myocardial glycogen pool turns over rapidly even when b-oxidation appears to satisfy a major proportion of the energy demand of the whole w x heart 84-86 . Additionally, myocardial glycogen is preferentially oxidized compared with exogenous glucose and therefore produces proportionately more ATP per mole of w x glucose metabolized 84,86 . The role of insulin in regulating glycogen turnover and in the preferential oxidation of glycogen-glucose remains to be investigated. Cardiac glycogen metabolism is further complicated by a marked transmural gradient of glycogen concentration and glucose metabolism-glycogen concentrations and rates of glucose uptake being highest in the innermost layers of muscle w x 87,88 . The differential distribution of glycogen may suggest a critical function in domains of muscle which may be forced to rely less on b-oxidation and indicates that the actions of insulin and other hormones may be expressed differentially through the myocardium.
The major mechanisms for regulation of the key enzymes of glycogen metabolism appear to be similar in w x heart and skeletal muscle 2,89 . Cardiac glycogen phosphorylase isozymes differ in some properties from the skeletal muscle form but are still activated both by phos-Ž . phorylation by phosphorylase kinase and by allosteric X w x ligands-particularly by 5 -AMP 90 . Cardiac phosphorylase kinase contains a distinct isoform of alpha-subunit Ž X . alpha , but, like its skeletal muscle counterpart, is phosphorylated and activated by cyclic AMP-dependent protein kinase and by binding of calcium to the intrinsic delta w x subunitrcalmodulin 91 . Cardiac glycogen synthase is activated by glucose-6-phosphate and also subject to multiw x ple-site phosphorylation 92,93 . Studies with purified heart glycogen synthase confirm phosphorylation and inactivation by PKA, GSK-3, calciumrcalmodulin kinase II, PKC and phosphorylase kinase with generation of phosphopeptides identical to those of synthase from skeletal muscle w x 94 . Insulin induces rapid dephosphorylation and activation of glycogen synthase in perfused hearts, promoting the formation of 'GS-I', the form of the enzyme which exhibits full activity independently of glucose-6-phosphate w x 95,96 . The results of the studies with isolated perfused w x hearts are supported by NMR studies in vivo 97 . It is important to note that insulin treatments do not appear to induce changes in cyclic AMP concentrations, the activation state of PKA or the proportion of glycogen phosphow x rylase in the active form in perfused hearts 98-100 , even when hearts are perfused in the presence of fatty acids w x 98 .
Why are heart glycogen reserves enhanced during diabetes, even though prevailing humoral conditions might be expected to induce glycogen depletion as in skeletal muscle and liver? Glycogen accumulates in the diabetic heart despite the fact that glycogen synthase expression is not w x elevated in hearts of STZ-diabetic rats 101 or in human w x Type II diabetics 102 . In addition, the level of GS-I is w x markedly suppressed 95 and the ability of insulin to w x induce activation is severely blunted 98,101,102 . The ( )defect in activation of glycogen synthase is associated with decreases in the levels and insulin-mediated activation of glycogen synthase phosphatase in experimental and human w x diabetes 100 ; this observation further underlines the importance of the activation of protein serinerthreonine phosphatases in insulin action. The accumulation of glycogen when the activation of glycogen synthase is decreased indicates that flux through glycogen phosphorylase must also be diminished, even though glycogen phosphorylase is expressed at near-normal levels in the diabetic heart w x 98,100 and is 'hypersensitive' to catecholamine-mediated w x stimulation 99,103 . Taken together, these observations support an earlier suggestion that the effects of phosphorylation of the glycogen-metabolizing enzymes are likely to be over-ridden by availability of allosteric regulators in the w x heart, at least in some conditions 45 .
PyruÕate oxidation
Ž . The pyruvate dehydrogenase complex PDC is a major target for insulin action. The effects of insulin arise through control of delivery of substrates to the myocardium and also by direct effects of insulin on PDC specific activity. The regulation of PDC involves interactions between covaw x lent phosphorylation 104 and non-covalent mechanisms, principally accumulation of reaction products. Most di-Ž rectly, the rise in intramitochondrial acetyl-CoA and fall . in free CoA , occasioned by enhanced rates of oxidation of fatty acids or ketones, causes product inhibition of PDC w x 105 . In addition, the associated PDC kinase becomes activated and, by phosphorylating three sites on the a-sub-Ž . unit of the pyruvate dehydrogenase E1 components of the complex, converts the complex into a phosphorylated w x form with very low specific activity 106 . The importance of the regulation of PDC activity in overall glucose metabolism is perhaps most clearly revealed by studies with dichloroacetate, which potently inhibits PDC kinase w x and therefore activates PDC and pyruvate oxidation 107 .
In addition to reducing the availability of exogenous Ž fatty acids for oxidation and thereby reducing the level of . intramitochondrial acetyl-CoA , exposure of hearts to inw x sulin leads to rapid and direct activation of PDC 108 . Insulin-mediated activation of PDC persists in isolated mitochondria; however, the mechanism for the effect of w x insulin is still not fully understood 109 . The activation of the complex is probably explained by increases in PDCw x 2q phosphate phosphatase 110 , which is dependent on Mg 2q w x for activity and is further stimulated by Ca 108-111 . Consequently, PDC can be activated by increases in cytoplasmic and hence mitochondrial calcium in the heart w x 112 , but calcium ions alone do not account for the effects w x of insulin, which acts by a distinct mechanism 113,114 . Overall, the mechanical demands of the heart dictate the level of activation of the TCA cycle through effects on the intramitochondrial concentrations of NADHrNAD, 2q w x ATPrADP and Ca 109,115 . The primary role of insulin in this context is to induce a switch in selection of substrates used to provide acetyl-CoA.
The regulation of PDC in diabetes involves not only the short-term mechanisms described but also effects mediated by protein synthesis. The expression of PDC itself changes very little but that of PDC kinase is enhanced in starvation Ž . and experimental diabetes Table 2 , suggesting that insulin plays a tonic inhibitory role in the expression of this w x intramitochondrial protein kinase 116,117 . Taken together, the mechanisms for regulating PDC exert profound effects on overall glucose utilization, including mechanisms to transmit control to additional metabolic enzymes.
Glycolysis
Regulation of GLUT and PDC activity has an important bearing on flux through glycolysis which is generally coordinated with rates of pyruvate oxidation, increasing in response to insulin and to increased cardiac workload w x during glucose perfusion 37,45,118 . 'Uncoupling' of glycolysis and pyruvate oxidation is possible, being most Ž apparent in hypoxia or anoxia when glycolysis is markedly activated but terminal oxidation of pyruvate and fatty acids . is precluded but also evident even under normoxic conditions. Other conditions, such as reperfusion after ischemia w x Ž . 38 and cardiac hypertrophy see Section 6 , may also disrupt the balance between glycolysis and glucose oxidation.
Ž . The regulation of 6-phosphofructo-1-kinase PFK-1 is critical in the control of glycolysis. Normal tissue levels of key allosteric inhibitors, ATP and citrate, ensure that the enzyme is inactive unless allosteric activators are also available. Fructose-2,6-bisphosphate, the product of the Ž . dual function 6-phosphofructo-2-kinase PFK-2 rfructose-2,6-bisphosphatase, is a critical modulator of cardiac PFK-1 because it is able to overcome the inhibitory effects of w x ATP 119,120 . The cardiac form of PFK-2 likely plays a significant role in the activation of glycolysis in response w x to insulin 121 , and although the mechanism is not understood, it appears to be wortmannin-sensitive. Levels of fructose-2,6-bisphosphate are also increased during increases in cardiac workload and contribute to corresponding increases in rates of glycolysis. Importantly, the distinct cardiac PFK-2 isoform is not inhibited upon incubaw x tion in vitro in the presence of PKA 122 . This property of the cardiac form of PFK-2 is in sharp contrast to the response of the hepatic isoform, which is markedly inhibited by PKA in concert with the activation of the fructose w x bisphosphatase active site 120,123 . Consequently, phosphorylation of hepatic PFK-2 by PKA contributes to inhibition of glycolysis by catecholamines and glucagon and facilitates gluconeogenesis and hepatic glucose output. In the heart, glycolysis is stimulated by catecholamines and by insulin. PFK-2, like PFK-1, is inhibited by citrate, so 
and to suppress the formation of the PFK-1 activator, fructose-2,6-bisphosphate.
Insulin also exerts a rapid influence on hexokinase, largely indirectly, through changes in PFK-1 and PDC. Inhibition of PFK-1 and of PDC, when insulin levels are low, lead to accumulation of fructose-6-phosphate and then Ž . via phosphoglucose isomerase of glucose-6-phosphate which inhibits hexokinase. Stimulation of PFK-1 by insulin therefore relieves inhibition of hexokinase by glucose-6-phosphate. The possibility that insulin might regulate expression of hexokinase was suggested by studies of w
Fatty acid metabolism
We have discussed the roles of insulin in regulating the supply of exogenous fatty acids to the myocardium-notably at the level of adipose tissue and liver to control circulating levels of free fatty acids and lipoprotein triglycerides. Insulin also regulates fatty acid metabolism within the heart itself. The regulation of glucose transport and of PDC provide important means to modulate fatty acid oxidation, the latter being notably revealed by the actions w x w x of pyruvate 128,129 and dichloroacetate 107 . There are additional steps which also contribute to the regulation of fuel selection in the myocardium. Here we discuss the effects of insulin on triglyceride lipases and on carnitine Ž . palmitoyl transferase-I CPT-I , critical enzymes of lipid metabolism in the heart. Fatty acids may be generated in the myocardium by release from triglycerides in the plasma lipoproteins as w x well as from endogenous tissue triglyceride stores 130 . The hydrolysis of plasma triglycerides is effected at the luminal surface of vascular endothelial cells, but the Ž . lipoprotein lipase LPL which is responsible is synthesized in cardiac myocytes and this process is regulated by insulin. The expression of cardiac LPL is sustained during Ž moderate starvation while the adipose tissue enzyme is . repressed and this contributes to the channelling of lipid w x fuels from adipose tissue to muscle 23,24 . In contrast, the expression of LPL is inhibited in experimental diabetes in w x heart and skeletal muscle as well as in fat tissue 25,131 . The effects of insulin on lipoprotein lipase are complex and incompletely understood-indeed, the steps involved in the maturation and processing of LPL from synthesis to localization in vascular endothelial cells are still not fully 133 . The decline in LPL levels, coupled with altered properties of the circulating lipoproteins, combines to markedly reduce the utilization of circulating triglycerides w x by the diabetic heart 133,134 . The LPL activity recovered from cardiomyocytes is also reduced by STZ-diabetes w x 135 , the reduction being explained partly by a decline in general protein synthesis and partly by a defect in processing of the enzyme to the fully active form. Interestingly, no changes in LPL mRNA abundance or turnover were w x detected during 4-5 days of STZ-diabetes 136 .
The Fatty acid oxidation is also regulated in the heartespecially by control of carnitine palmitoyl transferase-I Ž . CPT-I . A critical mechanism for regulating CPT-I, through allosteric inhibition by malonyl CoA, was elucidated as a result of studies of hepatic fatty acid oxidation w x Ž . and ketogenesis 149 . The distinct 'M' 'muscle' isoform of CPT-I represents 98% of the total activity in adult heart w x 150 ; it exhibits a higher K for carnitine and lower IC 155 . The heart expresses a distinct 280-kDa isoform of acetyl-CoA w x carboxylase 156,157 which appears to play a significant role in regulating fatty acid oxidation in the heart, judging by the inverse relationship between rates of fatty acid oxidation and tissue concentrations of malonyl-CoA w x 38,158 . The larger 280-kDa isoform of acetyl-CoA carboxylase displays a higher K for acetyl-CoA than the m w x 265-kDa isoform found in adipose tissue and liver 156 and substantial differences in primary structure have been w x detected 159 . The mechanism by which acetyl-CoA carboxylase might be regulated by insulin in the heart is not resolved-no effects of insulin on the activity of the cardiac enzyme have yet been demonstrated to persist following enzyme extraction or purification. It has been suggested that the supply of acetyl-CoA might limit the w x formation of malonyl-CoA in the heart 38,160 , but cytoplasmic acetyl-CoA levels are highest in the heart when Ž fatty acid oxidation is predominant and when the ACC . activator citrate is most abundant . These observations suggest that some additional mechanism must restrict cardiac acetyl-CoA carboxylase in starvation and diabetes. The multiple-site phosphorylation of the 265-kDa form of w x acetyl-CoA carboxylase 155,161,162 suggests that this mechanism might also be significant in regulating the 280-kDa isoform of the enzyme in the heart. Our own recent studies have demonstrated the phosphorylation of acetyl-CoA carboxylase within rat cardiac myocytes and shown that the 280-kDa isoform is indeed phosphorylated w at multiple sites Boone, Rodrigues and Brownsey, unpubx lished observations . It will be important to establish which cellular protein kinases are most important in the phosphorylation of the cardiac ACC isoform and what effects, if any, are induced by insulin. In adipose tissue and liver, acetyl-CoA carboxylase is phosphorylated and inhibited in response to catecholamines and glucagon, most likely through the actions of the AMP-activated protein kinase w x 161-164 . This protein kinase may also play a significant role in regulating acetyl-CoA carboxylase in the heart. For example, in hearts subjected to ischemia and reperfusion, formation of malonyl-CoA is decreased in parallel with enhanced rates of fatty acid oxidation and activation of w x AMP-activated protein kinase 165 .
Additional mechanisms for regulating fatty acid oxidation through the availability of malonyl-CoA are also possible. For example, it has been suggested that only a small proportion of total tissue malonyl-CoA may be accessible to CPT-I, raising the possibility that compartmentation or binding of this inhibitor could be a regulated w x process 166 . Finally, since the heart appears to express w x no fatty acid synthase 167 , a mechanism for malonyl-CoA removal must be available and may be regulated. MalonylCoA decarboxylase has been described in mitochondria w x from various rat tissues 168 and activity in the heart appears to be increased during reperfusion following isw x chemia 169 . A detailed examination of cardiac malonylCoA decarboxylase and of its regulatory properties is clearly merited.
Intracellular signalling pathways in insulin action
From the foregoing discussions, it is clear that the effects of insulin on key metabolic enzymes and transporters and on myocardial metabolic pathways are well defined. It is therefore important to establish the intracellular signalling mechanisms which may lead to the regulation of glucose transport proteins and enzymes important in the control of cardiac energy metabolism. Recent reviews have provided detailed accounts of our current understanding of the molecular basis for insulin action w x 1-4 . Our goal is to outline the major features of insulin action established as a 'consensus' from diverse cell types and examine the evidence which indicates if the same or distinct signalling elements operate in the heart. We first discuss the activity of the insulin receptor and the proteins Ž . with which it directly communicates Fig. 3 ; we then evaluate distinct pathways for intracellular signalling which are likely to be required to explain the pleiotropic effects Ž . of insulin Table 3 .
The insulin receptor-subunit structure and hormone binding
The structure and function of the insulin receptor has been intensively studied and new insights continue to w x emerge 4,170 . The functional tetrameric receptor is com-Ž . prised of two dimers, each made up of a-135-kDa and Ž . b-95-kDa subunits. The a-and b-subunits are derived w x from a single, contiguous precursor 171,172 by proteolytic cleavage and processing, which includes complex Ž . glycosylation. A disulfide bond likely involving Cys-647 couples the C-terminal domain of each a-subunit to the small exofacial domain of the corresponding partner bw x subunit 1,170 ; further disulfide bonds also form between the cysteine-rich domains of the two a-subunits of each intact receptor, so that the disulfide bridging pattern of w x each tetramer is b-a-a-b 1,4,170 . Once the receptor is assembled in the plasma membrane, the a-subunits are entirely extracellular and bind insulin by a mechanism w x which displays apparent negative cooperativity 173 . Cross-linking studies with photo-activated insulins suggest important determinants for insulin binding are found in both the N-terminal and the C-terminal domains of the w x receptor a-subunits 174,175 .
Among two possible receptor isoforms expressed in mammalian cells, the higher-affinity 'A'-isoform is by far the predominant form expressed in the heart, contributing w x more than 95% of the total 176 . The A-isoform of the insulin receptor differs from the alternate B isoform because of differential splicing of a common mRNA which 
Ž
. Ž may lead to the deletion in isoform A or inclusion in . isoform B of exon 11 and the corresponding 12-amino-acid residues beginning at position 717 of the a-subunit Cterminus. Alterations in expression of the receptor isoforms has been reported in skeletal muscle of patients with Type II diabetes, in which the B-isoform is expressed at Ž . Five potentially discrete signalling pathways may be identified on the basis of sensitivity to wortmannin andror LY294002 andror rapamycin, coupled Ž . with experiments in which the PI-3-kinase p85rp110 is specifically ablated by site-directed mutagenesis. The effects of insulin on several enzymes are Ž wortmannin-sensitive but assignment to a signalling pathway is not yet certain e.g. protein phosphatase-1G, PFK-2, ACC, PDE-III CPT-I and hormone-sensitive lipase. Note that the pathway to PDC-P phosphatase must also signal across the mitochondrial membranes. Nuclear signalling may Ž . require translocation of a basally cytosolic transcription factor such as STAT3 , an appropriate protein kinase or phosphatase, or other modulators.
Ž . Regulation of transcription factors via the MAP kinase ERK pathway may involve direct phosphorylation by ERK-1 or ERK-2 or by p90rsk. STAT signalling has been omitted from this table because its role and sensitivity to the reagents described have not yet been established. unusually high levels 177 . The possibility that receptor isoform 'switching' may occur in the heart has not been explored, but could be important given the distinct proper-Ž . ties of the isoforms; the A-isoform -exon 11 displays approximately 2-fold higher sensitivity to insulin, but the B isoform expresses substantially higher intrinsic and inw x sulin-stimulated protein tyrosine kinase activity 176,178 .
Determination of the abundance of functional insulin receptors in myocytes within the intact heart has been complicated by the substantial numbers of endothelial receptors and the requirement for trans-endothelial transport of the hormone to reach the surface of myocardial w x cells 179 . However, many in vivo and in vitro studies attest to the sensitivity of the heart to insulin over a physiological concentration range of 10-200 mUrml, or w x 0.1-2 nM 97,101,180 . Since tissue sensitivity to insulin w x is dictated by receptor abundance 181 the density of functional insulin receptors in the heart is probably in the Ž range found in other insulin-sensitive cell types 10 000-. 100 000 per cell .
ActiÕation of the insulin receptor protein tyrosine kinase
The insulin receptor is a transmembrane allosteric enzyme in which insulin binding induces autophosphorylation and activation of the protein tyrosine kinase domain on the cytoplasmic aspect of the transmembrane b-subunits. The fact that limited trypsin treatment can cause receptor activation and that mutant receptors with trun-Ž . cated a-subunits as well as isolated kinase domains are constitutively active suggest that the a-subunits exert a tonic inhibitory effect on the protein tyrosine kinase of the w x b -subunit 1,4,170 .
On the basis of experimental studies, it is evident that most aspects of insulin signalling appear to depend on a w x functional receptor kinase 1,4,170 . In addition, a number of clinical cases of severe insulin resistance have been described which appear to be accounted for by natural mutations in the insulin receptor gene which are associated w x with loss of receptor kinase activity 182 . A triplet of Ž closely-spaced tyrosines residues Y-1158, Y-1162 and . Y-1163 in the receptor b-subunits become phosphorylated w x in the full activation of the kinase domain 183,184 . Recent crystallographic studies of the isolated kinase subdomain reveal that the activation of the receptor kinase requires the removal of an autoinhibitory loop from the active site, associated with the autophosphorylation by the Ž . w x kinase domain of the partner 'trans' b-subunit 185 . Additional sites for tyrosyl and serylrthreonyl phosphorylation also occur in the juxtamembrane and C-terminal domains of the b-subunits, notably tyrosines 953, 960, 1328 and 1334 plus SerrThr residues 1272, 1305r1306 w x and 1327 170 . The functional significance of these additional receptor phosphorylation sites is discussed below; it is clearly vital to establish if the sites play equivalent roles in the heart.
Intracellular proteins which interact with the insulin receptor
Among the immediate targets of the insulin receptor, the most extensively studied has been IRS-1-the w x 'insulin-receptor substrate 1' 1,186 . Originally observed w x as a prominent 185-kDa phosphoprotein 187 , this soluble protein becomes phosphorylated in response to insulin on at least 8 out of 20 potential tyrosine phosphorylation sites. These sites occur within Y-X-X-M motifs which are recognized by several defined proteins which contain SH2 Ž . src-homology 2 domains. IRS-1 therefore appears to act as a nucleation site for the assembly of subsequent down-Ž . stream signalling proteins or complexes Fig. 3 . Proteins with SH2 domains which associate with IRS-1 include the adaptor proteins Grb2 and Nck, the protein tyrosine phosphatase SH-PTP2rSyp and 'p85', the 85-kDa regulatory w x subunit of PI-3-kinase [188] [189] [190] . Studies of transgenic mice in which IRS-1 is ablated suggested that a related 'IRS-2' protein must also play a critical role in insulin w x actions in vivo 191 . The structure of IRS-2 has been reported but details of its functions have not yet been w x established 192,193 . In addition to IRS proteins, other recognized targets of Ž . the insulin receptor exist Fig. 3 . One of the additional receptor targets for which a functional role has been established is Shc, which binds directly to activated insulin receptors and becomes tyrosine-phosphorylated in rew x sponse to insulin 194 . Among several isoforms of Shc the w x insulin receptor may favour the 52-kDa isoform 195 . The identification of Shc isoforms, together with IRS proteins and the newly-emerging ShcB, ShcC and Grb10, shows that the range of insulin receptor targets is likely to be w x appreciable 196, 197 . It will be an important challenge to determine which of these receptor targets play critical roles in mediating the effects of insulin in the heart.
Signal transducing 'adaptor' proteins such as IRS and Shc can form cross-links between two or more proteins because they contain multiple interaction domains. In IRS and Shc, for example, the PTB domains contact the insulin receptor juxtamembrane domain while SH2 binding sites can be generated within these adaptors when they become tyrosine-phosphorylated. Shc may additionally attract SH3-containing proteins because of its proline-rich motifs. w x The 85-kDa subunit of PI-3-kinase 198 or the tyrosine w x phosphatase Syp 199 may also serve to cross-link IRS-1 with the insulin receptor because they each have two SH2 domains. An important consequence of the multiple protein-protein contacts described is the possibility of the formation of multimolecular signalling complexes at the plasma membrane. These complexes might pre-exist in a non-active conformation in the absence of hormone stimu- 
IRS proteins and multiple metabolic signalling pathways
Reluctantly, we must concede that our understanding of the signal transmission pathways which mediate the metabolic effects of insulin are poorly understood even in muscle, fat and liver. In particular, it is becoming evident that several routes for metabolic signal transmission can be discriminated, so that reagents which interfere with certain insulin actions do not necessarily affect others. The complexity of the array of proteins which can interact at the Ž plasma membrane with the insulin receptor directly, or in . larger complexes may indeed be giving us a foresight of the complexity of post-receptor pathways.
Considerable interest has been generated by studies Ž employing wortmannin and other agents including . LY294002 which profoundly inhibit many metabolic effects of insulin, including glucose transport, glycogen synw x thesis, lipogenesis and antilipolysis [200] [201] [202] . Wortmannin potently inhibits PI-3-kinase, though it is not completely selective. Studies in which cells have been transfected with constitutively active or dominant negative mutants of PI-3-kinase confirm that the stimulation of GLUT-4 is strictly dependent on PI-3-kinase itself; in contrast, other insulin responses including activation of glycogen synthesis and of p70-S6 kinases involve wortmannin-sensitive w x steps distinct from PI-3-kinase 201,202 .
Events downstream from PI-3-kinase are still poorly defined. PKC-z may be a cellular target of PI-3,4,5-trisphosphate, one of the major products of the PI-3-kinase w x reaction 203 , but the consequences of activation of this PKC isoform by insulin have not been established. Another possibility is the recently-discovered protein serinerthreonine kinase PKB, which is rapidly activated w x by insulin in fat and muscle cells 204 and may be a critical mediator of insulin signals from PI-3-kinase to w x glycogen synthase kinase-3 205 . The activation of PKB is w x dependent upon its phosphorylation 206 , perhaps by PI-3-kinase which expresses protein serine as well as lipid w x kinase activity 207 but more likely through an intermediw x ate 'PKB-kinase' 205 . Although we currently understand little of the mechanism of activation of PKB or of its major substrates, nevertheless, the expression of PKB in w insulin-sensitive cells including the heart Zhande and x Brownsey, unpublished observations , its sensitivity to wortmannin, ability to influence GSK-3 and ability to stimulate GLUT-4 and lipogenesis suggest it could be critical in metabolic signalling and merits further investigaw x tion in the heart 205,208 .
( ) 5.5. Shc and the MAP kinase ERK signalling pathway
Shc plays a critical role in mediating the mitogenic or growth-promoting effects of insulin, IGF-1 and EGF, at least in part through activating the p21-RasrMAP kinase Ž . w x ERK pathway 209 . Corresponding experiments with heart cells have not yet been reported, although the possibility that insulin might act as a signal for hypertrophy in Ž . some situations is discussed below Section 6 . An important SH2-containing target attracted by tyrosine-phosphorylated Shc is Grb-2 which also contains SH3 domains w x able to contact the proline-rich sequences of Sos 210 . While complexed with Grb2, Sos acts as a guanine nuw x cleotide exchange factor of the p21-Ras GTPase 211 . Binding of GrbrSos to Shc at the plasma membrane 'receptor complex' thus brings about the activation of p21-Ras by enhancing release of GDP and its replacement with GTP.
The activation of p21-Ras promotes the activation of a sequence of protein kinases, known as the 'MAP kinase w x cascade' 2,212,213 . Because the MAP kinases were initially discovered as the activity in 3T3-L1 adipocytes responsible for the insulin-stimulated phosphorylation of Ž . w x the microtubule-associated protein MAP -2 214 , this system has considerably influenced our thinking about Ž . insulin signal transduction. p21-Ras GTP is able to bind Ž . directly through its N-terminal domain to the protein w x serinerthreonine kinase c-Raf-1 215 as well as to a w x functional equivalent of Raf-1 named 'MEKK1' 216 . The interaction with p21-Ras leads to recruitment of Raf-1 to w x the plasma membrane 217 , but this is not sufficient for Raf-1 activation. PKC isoforms have been shown to directly phosphorylate Raf-1 in vitro and might play a role in its activation; however, it has recently been proposed that Raf-1 activation is explained by oligomerization and assow x ciation with 14-3-3 proteins 218,219 . Consequently, insulin signalling from the receptor to Raf-1 must likely occur at the plasma membrane and further steps are required before signals may be emitted to the cytosol or beyond. Following activation, Raf-1 is then able to phos-Ž . phorylate and activate MAP kinase kinases MEKs which w x are consequently activated 220 . MEK-1 and MEK-2 are dual-specificity protein kinases, able to phosphorylate threonine and tyrosine residues of the TEY motifs of their w x specific target MAP kinases, ERK-1 and ERK-2 221 .
The components of the response pathways for Ras-dependent and PKC-dependent activation of the MAP kinases are present and functional in the mature heart. MAP kinase function in the heart has been best studied in response to the endothelins, angiotensin and other growthw x promoting stimuli 222,223 , but responsiveness to insulin has not been established in the heart.
ERK-1 and ERK-2-a major role in rapid metabolic actions of insulin?
Initial studies indicated that glycogen metabolism could be regulated through ERK activation. MAPKAP kinase-1, the mammalian ; 90-kDa ribosomal protein S6 kinase Ž . p90rsk, or RSK2 was found to be phosphorylated and TCF rElk-1 which cooperates with the serum response factor in stimuw x lating the induction of c-fos and AP-1 activity 235,233 . In addition, the MAP kinase pathway may affect transcrip-Ž . tion from cyclic-AMP-response elements CRE through activation of p90rsk, which is able to phosphorylate the Ž . w x CREB CRE-binding proteins 236 . Finally, the ability of insulin to stimulate the serine phosphorylation of STAT3 may provide a particularly direct mechanism for insulin w x signalling to the nucleus 237 .
As with regulation of transcription factors, effects of insulin on protein synthesis have been recognized but are w x incompletely defined 17,238 . Several proteins important in regulating mRNA translation are phosphorylated in response to insulin, including the S6 protein of the 40S Ž ribosomes, initiation factors eIF-2B and eIF-4F including . the 4A, 4-a and 4-g subunits , the eIF-4E binding proteins Ž . eIF-4E:Bp, also called 'PHAS' and elongation factor eEF-2. The phosphorylation of the ribosomal S6 protein is most likely accounted for by the p70rp85 S6 kinases w x 239 , but the functional effects of phosphorylation are still not clear. The phosphorylation of the eIF-4F subunits is particularly attractive, because the 4a-subunit initiates binding to the 5 X -methyl guanosine 'cap' of mRNA and can potentially play a role in global and selective mRNA translation; this could be especially important in attempts to understand how insulin can specifically enhance translaw x tion of particular mRNA species 240 . So far, the protein kinases involved in the phosphorylation of the initiation and elongation factors have not been identified.
Summary of the impact of signalling pathways on key metabolic proteins
Ž .
i A number of routes for signal transduction from the insulin receptor have been deduced from studies with Ž 'selective' inhibitors of signalling proteins notably wort-. mannin, rapamycin and MEK inhibitors as well as the use of transgenic animals or transfected cells which express mutated signalling proteins.
Ž .
ii The regulation of PDC stands alone, so far, among metabolic responses to insulin, being insensitive to wortmannin. Understanding signal transmission from the insulin receptor to the matrix of mitochondria remains a significant challenge. Fundamental studies of PDC kinase and especially of PDC-P phosphatase will be central to this endeavour.
Ž . Ž . iii The MAP kinase ERK pathway and its activation via Shc andror IRS proteins is rather well defined, though the outputs from this pathway are still being identified. A major role for this pathway in mediating effects of insulin on gene transcription through phosphorylation of transcription factors such as Elk-1 and the CREBs seems likely, though the myocardial genes which might be controlled remain to be defined. ERK-mediated regulation of gene transcription might be complemented by insulin effects on the JNK pathway, but these kinase cascades appear to play Ž . iv Several discrete signalling routes are inhibited by wortmannin and related inhibitors. One route, to the activation of the p70-S6 kinase, is also inhibited by rapamycin and contributes to the regulation of mRNA translation, through phosphorylation of the ribosomal protein S6 and of the initiation factor 4E-binding proteins. Other targets downstream from p70-S6 kinases may yet become apparent.
v The wortmannin-sensitive responses to insulin which are unaffected by rapamycin can also be sub-divided according to the species of protein inhibited by wortmannin. The activation of glucose transport by insulin is mediated Ž . specifically by the well-characterized p85rp110 PI-3-kinase. Other insulin responses, including activation of PKB and glycogen synthase, appear to be mediated by wortmannin-sensitive proteins distinct from the established PI-3-kinase. The steps downstream from the wortmanninsensitive proteins are still poorly defined and yet account for some of the major metabolic actions of insulin, involving the regulation of PFK-2, glycogen synthase, acetyl-CoA carboxylase, PDE-III, hormone-sensitive lipase and the appropriate modulating protein kinases and phosphatases.
Clinical significance of defective insulin signalling
Alterations in the availability of insulin or in the functions of its signalling pathways may be involved in a number of physiologic and pathologic processes in the heart including the changes in metabolic function of the w x heart in the neonatal period 241,242 , insulin resistance w x w x associated with aging 243 , obesity 244 , non-insulin-dew x pendent diabetes mellitus 245 , essential hypertension w x w x 245,246 and cardiac hypertrophy 247 as well as the cardiomyopathy observed in patients with Type I and Type w x II diabetes mellitus 248,249 . Several of these topics are discussed elsewhere in this issue, so here we limit our discussion to brief comments to illustrate the actions of insulin in the setting of hypertension and cardiac hypertrophy.
Basal glucose uptake is enhanced into the myocardium w x of patients with hypertension 250 or experimental aniw x mals with cardiac hypertrophy 247,251 . However, insulin responses are diminished in hypertrophied hearts from w x spontaneously hypertensive rats 247 . These findings indicate that insulin-independent glucose uptake is accelerated and that insulin-dependent glucose uptake is impaired in hearts exposed to pressure overload. This conclusion is also supported by the decreased expression of GLUT-4 w x 247 and increased ratio of GLUT-1 to GLUT-4 mRNA w x 252 in hypertrophied hearts. Similarly, we have found that rates of glycolysis of exogenous glucose are accelerated in isolated working hypertrophied hearts from aorticw x banded rats 253-255 . The observed increases in insulinindependent glucose uptake and glycolysis are consistent with the demonstration that the activity of glycolytic enw x zymes is increased 256,257 and that the patterns of expression of the isoenzymes of lactate dehydrogenase w x w x 256 and enolase 242 in hypertrophied hearts reflect those seen in fetal, anaerobic hearts rather than normal adult hearts.
Accelerated rates of glycolysis of exogenous glucose in hypertrophied hearts are not accompanied by corresponding changes in glucose oxidation, and instead lead to an uncoupling between rates of glycolysis and oxidation of exogenous glucose that is significantly greater in the w x hypertrophied heart than the normal heart 253-255 . So far, the mechanisms responsible for the exaggerated uncoupling of glycolysis from glucose oxidation in hypertrophied hearts are not yet known. An important therapeutic point that arises from the fact that hearts exposed to a pressure overload are resistant to the metabolic effects of insulin, is that glucose-insulin-potassium infusion is unlikely to alter myocardial glucose utilization in this setting. Any benefits to myocardial metabolism of this therapeutic approach would more likely occur indirectly as a result of inhibition of adipose tissue hormone-sensitive lipase and consequent decreases in plasma concentrations of free fatty acids.
In addition to its metabolic effects, the actions of Ž . insulin on cellular gene expression Section 5 may also contribute to cardiac myocyte growth in hypertrophy and other clinical settings. Insulin resistance in patients with essential hypertension and non-insulin-dependent diabetes mellitus is characteristically accompanied by hyperinsuw x linemia 245 , raising the possibility that elevated levels of insulin play a role in the development of cardiac hypertrophy in these settings. Experimental observations which provide support for this concept include those showing direct effects of insulin on protein synthesis in isolated w x w x perfused hearts 258 and in cardiac myocytes 259 . Further, insulin increases the expression of cardiac hexokinase w x II 127 and contributes to determination of enolase isoenw x zyme expression 242 . These effects of insulin on glycolytic enzymes are in keeping with the recognized metabolic phenotype of hearts which exhibit hypertrophy as a result of pressure overload. Lastly, it has recently been shown that transgenic mice deficient in the GLUT-4 hexose transporter are hyperinsulinemic and develop signifiw x cant cardiac hypertrophy 260 .
The mechanisms by which insulin mediates its growthrelated effects in the heart are not yet established, but an important clue may be provided by the recent observation that rapamycin, which inhibits activation of p70-S6 kinase, also blocks the stimulation of overall protein synthesis induced by exposure of neonatal rat ventricular myocytes to angiotensin II, an important mediator of hypertrophic w x growth in the heart 261 . Since the activation of p70-S6 kinase by insulin is also rapamycin-sensitive 262 , it is tempting to speculate that the increased protein synthesis observed in cardiac myocytes exposed to insulin is, in part, mediated by this pathway.
Considering the morbidity and mortality associated with hypertensive heart disease and that alterations in insulin signalling and carbohydrate metabolism may play a pathogenetically important role, the need for investigation in this area is imperative.
Concluding comments
Ž .
i Reviewing the actions of insulin in the heart has been a humbling experience! On one hand, a remarkable amount of relevant work has been done in defining metabolic effects and key proteins which account for flux changes induced by insulin. On the other hand, our understanding of the intracellular mechanisms by which insulin signals are transmitted from the receptor to 'metabolic targets' is still fragmentary.
ii It is tempting and perhaps essential, at first, to infer that aspects of insulin signalling identified in diverse cell types will also be relevant in the heart. However, several observations raise concerns that this notion must be carefully qualified. The heart displays many unique features which suggest that regulation of cardiac function and metabolism may be distinct in important respects. For example, the heart maintains persistently high mechanical output and substantial consumption of oxygen and metabolic substrates which mean that 'metabolic control' is directed at the process of fuel selection, rather than at the major swings in flux which might be seen in skeletal muscle. The heart expresses distinct isoforms of a number Ž of key proteins including enzymes of glycogen metabolism, PFK-2, CPT-I, acetyl-CoA carboxylase and . others and expresses distinctive patterns of isoforms in other cases-such as the insulin receptor and GLUT proteins. The regulatory properties of the various protein isoforms is not established in all cases.
iii Even in the target cells and tissues which have been best studied, the intracellular mechanisms responsible for metabolic responses to insulin are not properly understood. A number of features of protein regulation must be integrated for a full understanding of insulin actions, which involve changes in the availability of substrates and allosteric modulators as well as protein-protein interactions -some of which lead to covalent changes is structure, notably phosphorylation or dephosphorylation.
Ž . iv The definition of signal transduction pathways in general and specifically those which mediate insulin's actions, challenge our ability to understand cell structure, organization and dynamics as well as our ability to define Ž . essential components. We are well advanced hopefully! in defining many of the essential components of insulin signalling pathways, but this process will certainly represent just one step in understanding how the systems operate in living cells. In the case of glucose transport, our understanding of insulin action has been limited by our lack of knowledge of the basic process of protein trafficking between membrane compartments and the associated vesicle budding and fusion processes.
v To what extent is it valid to view intracellular signalling events in a linear pathway or set of discrete linear pathways? In one sense, the pathway concept is helpful and indeed justified by the established ability of proteins to interact with specific partners and by the efficacy of reagents which affect some responses but not all. However, there are observations which suggest that the integrity of separate branches of insulin signalling is not absolute. For example, one might anticipate that the MAP Ž . kinase ERK cascade may proceed independently of PI-3-kinase. However, ERK activation is blocked by wortmannin. Does this simply reflect lack of selectivity of the reagent, or are there functional interactions between PI-3-kinase and p21-Ras, as suggested earlier? Similar deductions might be drawn from the fact that proteins such as Syp can serve a positive signalling function and should not necessarily be regarded solely as a regulatory or 'off' switch. These observations, and others, may provide indi-Ž rect evidence for a larger 'insulin receptor complex' hinted . in Fig. 3 within which protein-protein interactions may be appreciable, although ultimately limited by steric constraints.
Ž . vi A number of signal transduction proteins appear to subserve the functions of more than one hormone, thereby acting as mobile 'modules'. For example, it has become evident that the activation of p21-Ras and the MAP kinase Ž . ERK pathway may be initiated by many hormones via Ž receptor tyrosine kinases and by G-protein subunits probably acting themselves on non-receptor protein tyrosine . kinases . It has recently emerged that angiotensin can even induce tyrosyl phosphorylation of the IRS-1 protein in the w x heart 263 . It will be intriguing to establish if the angiotensin-mediated effects on IRS-1 are identical to those seen with insulin and how this affects downstream responses. The important question raised by the multi-purpose roles of signalling molecules is one of selectivity. Why does insulin induce the range of effects it does, if it is only one of many possible mediators of, say, the MAP Ž . kinase pathway or of PI-3-kinase etc . One general solution is presumably in the characteristic functional proteins which are modulated in a given cell type which expresses high levels of insulin receptors. In addition, we will likely have to develop a broader understanding of the entire range of responses to insulin in order to fully appreciate the context within which the function of specific protein kinases and phosphatases etc are expressed.
Ž . vii Despite the wealth of knowledge already gained, it is undeniable that a great deal more must be learned before we can truthfully conclude that we understand how insulin works in the heart. Even a cursory inspection of the evidence which points to the clinical significance of defects in insulin action will remind us that continued progress is essential. 
